Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD) and Amgen (AMGN).
Gilead Sciences (GILD)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Gilead Sciences, with a price target of $86.00. The company’s shares closed last Monday at $67.01.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.0% and a 54.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $77.08, which is a 14.7% upside from current levels. In a report issued on February 4, Mizuho Securities also maintained a Buy rating on the stock with a $81.00 price target.
See today’s analyst top recommended stocks >>
Amgen (AMGN)
RBC Capital analyst Kennen MacKay maintained a Hold rating on Amgen yesterday and set a price target of $236.00. The company’s shares closed last Monday at $222.71.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 15.4% and a 59.8% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, BioMarin Pharmaceutical, and Five Prime Therapeutics.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $247.56.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.